Crinetics Pharmaceuticals Overview
Crinetics Pharmaceuticals Target Price
Analysts' 12-month price predictions for CRNX.
Get informed when a big investor buys or sells
+ FollowShare Price
$42.23
Average Target Price
$78.20
85.2% upside
85.2% upside5 analysts in the last 4 months
High: $88 | Low: $55
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-02 | UBSAshwani Verma | $55 | 30.2% upside |  |
| 2026-06-22 | Stifel NicolausAlex Thompson | $83 | 96.5% upside | |
| 2026-06-15 | H.C. WainwrightDouglas Tsao | $81 | 91.8% upside | |
| 2026-05-15 | Evercore ISIGavin Clark-Gartner | $88 | 108.4% upside | |
| 2026-05-11 | Oppenheimer | $84 | 98.9% upside | |
| 2026-01-30 | Stifel Nicolaus | $84 | 98.9% upside | |
| 2026-01-12 | Goldman SachsRichard Law | $67 | 58.7% upside | |
| 2026-01-08 | Morgan Stanley | $87 | 106% upside | |
| 2026-01-08 | China Renaissance Securities (US) Inc. | $105 | 148.6% upside | |
| 2026-01-05 | Evercore ISI | $90 | 113.1% upside | |
| 2026-01-05 | Stifel NicolausAlex Thompson | $75 | 77.6% upside | |
| 2025-09-30 | Oppenheimer | $87 | 106% upside | |
| 2025-09-28 | Morgan Stanley | $77 | 82.3% upside | |
| 2025-09-26 | JMP SecuritiesJonathan Wolleben | $143 | 238.6% upside | |
| 2025-07-10 | Goldman SachsRichard Law | $36 |  14.8% downside | |
| 2025-03-24 | Stifel NicolausAlex Thompson | $60 | 42.1% upside | |
| 2025-02-28 | JMP Securities | $91 | 115.5% upside | |
| 2024-08-09 | H.C. WainwrightDouglas Tsao | $69 | 63.4% upside | |
| 2024-06-04 | OppenheimerLeland Gershell | $74 | 75.2% upside | |
| 2024-05-23 | Robert W. BairdBrian Skorney | $62 | 46.8% upside | |
| 2024-05-22 | Morgan StanleyJeffrey Hung | $70 | 65.8% upside | |
| 2024-05-07 | Piper SandlerYasmeen Rahimi | $97 | 129.7% upside | |
| 2024-03-20 | JMP SecuritiesJonathan Wolleben | $80 | 89.4% upside | |
| 2024-03-13 | OppenheimerLeland Gershell | $54 | 27.9% upside | |
| 2023-08-31 | OppenheimerLeland Gershell | $40 | 5.3% downside | |
| 2022-05-26 | Leerink Partners | $39 | 7.6% downside | |